27 November 2024 : Clinical Research
Evaluation of Cardiometabolic Risk in Patients with Non-Functioning Adrenal Adenomas Using the Systematic Coronary Risk Evaluation 2 (SCORE2) and the Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP) Algorithms
Marzena Jabczyk
1ABDEF, Justyna Nowak 2ABCDE*, Sylwia Mielcarska 3CD, Bartosz Hudzik 2AC, Kinga Wołkowska-Pokrywa 3B, Elżbieta Świętochowska 3BC, Barbara Zubelewicz-Szkodzińska 14ABEFG
DOI: 10.12659/MSM.945899
Med Sci Monit 2024; 30:e945899
Table 1 Comparison of baseline clinical characteristics between the SCORE2 and SCORE2-OP groups.
| Parameter | CVD risk based on SCORE-OP/SCORE-OP2 | P value | ||
|---|---|---|---|---|
| Low and moderate risk (N=16) | High risk (N=28) | Very high risk (N=62) | ||
| Sex: Women, n (%) | 16 (100) | 21 (75) | 41 (66.13) | 0.003 |
| Age [years] | 47.94 (5.37) | 59.21 (6.45) | 66.22 (7.48) | ,,a |
| TSH [uIU/ml] | 1.48 (0.86–1.96) | 1.10 (0.69–1.91) | 1.45 (0.94–1.96) | 0.2826 |
| fT3 [pmol/L] | 2.71 (2.60–2.92) | 3.07 (2.69–3.39) | 2.84 (2.58–3.13) | 0.4033 |
| fT4 [pmol/L] | 1.02 (0.94–1.05) | 0.97 (0.91–1.06) | 1.02 (0.93–1.10) | 0.67 |
| Na [mmol/L] | 139.5 (138.5–141.0) | 141.0 (140.0–143.0) | 140.0 (138.0–142.0) | ,b |
| K [mmol/L] | 4.16±0.46 | 4.28±0.39 | 4.33±0.47 | 0.48 |
| Leucocytes [10/mm] | 6.07 (5.715–7.16) | 6.75 (5.15–7.65) | 7.20 (6.24–8.54) | 0.058 |
| Erythrocytes [10/mm] | 4.64 (4.48–4.86) | 4.72 (4.42–4.88) | 4.78 (4.54–5.06) | 0.412 |
| Hemoglobin [g/dl] | 13.60 (13.05–14.15) | 14.05 (12.70–14.70) | 14.40 (13.50–15.30) | a |
| Hematocrit [%] | 41.20 (39.60–42.30) | 42.55 (39.90–44.40) | 42.90 (41.05–45.10) | 0.11 |
| Plates [10/mm] | 285.00 (253.00–322.00) | 248.50 (208.00–292.00) | 238.50 (203.50–294.50) | 0.2394 |
| CRP [mg/l] | 2.0 (0.80–3.9) | 1.3 (0.53–2.3) | 1.75 (0.94–2.8) | 0.29 |
| Cortisol 8: 00 a.m. [nmol/L] | 9.25 (7.35–10.65) | 10.90 (8.50–14.45) | 11.60 (9.20–13.50) | 0.0857 |
| Cortisol 6: 00 p.m. [nmol/L] | 5.60 (3.40–6.45) | 5.90 (4.60–6.90) | 5.60 (3.85–7.7) | 0.5271 |
| Cortisol 0: 00 a.m. [nmol/L] | 1.80 (1.35–3.25) | 2.55 (1.15–4.15) | 2.30 (1.70–4.00) | 0.4255 |
| ACTH 8.00 a.m. [pmol/L] | 9.50 (7.60–15.00) | 11.40 (9.20–21.60) | 14.60 (10.60–21.40) | 0.2414 |
| ACTH 6.00 p.m. [pmol/L] | 8.80 (6.94–12.20) | 9.25 (6.10–14.40) | 9.40 (7.10–14.00) | 0.8334 |
| Cortisol in urine [μg/24 h] | 27.60 (15.00–36.00) | 45.40 (31.60–60.10) | 36.80 (24.30–58.00) | 0.0347 |
| Aldosterone while the person is at rest [nmol/L] | 9.75 (7.40–37.50) | 8.50 (5.50–70.00) | 10.60 (5.70–59.00) | 0.9153 |
| Aldosterone while the person is in motion [nmol/L] | 19.1 (10.90–39.30) | 20.15 (6.40–84.30) | 17.45 (6.75–66.25) | 0.9616 |
| Renin while the person is at rest [nmol/L] | 7.61 (1.05–12.00) | 2.21 (0.81–13.40) | 8.11 (3.56–45.39) | 0.0736 |
| Renin while the person is motion [nmol/L] | 11.94 (2.36–28.00) | 2.83 (0.81–25.19) | 16.06 (6.38–87.03) | 0.0546 |
| DHEAS [μmol/L] | 95.70 (66.80–162.80) | 102.45 (59.30–146.15) | 85.10 (65.40–165.20) | 0.8402 |
| Systolic blood pressure [mmHg] | 130.00 (120.00–130.00) | 130.00 (130.00–140.00) | 140.00 (130.00–150.00) | ,,a |
| Diastolic blood pressure [mmHg] | 80.00 (75.00–80.00) | 80.00 (80.00) | 80.00 (80.00–90.00) | 0.55 |
| Hypertension, n (%) | 5 (31.25) | 6 (21.42) | 29 (46.77) | 0.1 |
| Impaired fasting glucose, n (%) | 2 (1.25) | 8 (28.57) | 9 (14.52) | 0.21 |
| Impaired glucose tolerance, n (%) | 1 (0.06) | 5 (17.86) | 10 (16.13) | 0.51 |
| Insulin resistance, n (%) | 3 (18.75) | 2 (0.070 | 2 (3.26) | 0.10 |
| Hypothyroidism, n (%) | 3 (18.75) | 1 (0.04) | 9 (14.52) | 0.25 |
| Hyperthyroidism, n (%) | 0 (0) | 3 (10.71) | 0 (0) | |
| Chronic autoimmune thyroiditis, n (%) | 3 (18.75) | 1 (0.04) | 9 (14.52) | 0.25 |
| TSH – thyroid stimulating hormone; FT3 – free triiodothyronine; FT4 – free thyroxine; Na – sodium; K – potassium; CRP – C-reactive protein; ACTH – adrenocorticotropic hormone; DHEAS – dehydroisoandrosterone sulphate. a Kruskall-Wallis test: significant difference for: low risk vs high risk; b Kruskall-Wallis test: significant difference for: low risk vs moderate risk; c Kruskall-Wallis test: significant difference for: moderate risk vs high risk. | ||||